MRNA

Moderna Inc

MRNA, USA

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

https://www.modernatx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MRNA
stock
MRNA

New mRNA flu shot moves to major trial in push to blunt the next pandemic Stock Titan

Read more →
MRNA
stock
MRNA

Two early mRNA firms join forces as BioNTech buys CureVac Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$37.2105

Analyst Picks

Strong Buy

5

Buy

1

Hold

17

Sell

3

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.24

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-2.14 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-1.65 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-86.61 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.30

Low 1

High 0.3

Investors

* Institutions hold a combined 79.61% of the total shares of Moderna Inc

1.

Vanguard Group Inc

(10.7198%)

since

2025/06/30

2.

BlackRock Inc

(7.3536%)

since

2025/06/30

3.

Baillie Gifford & Co Limited.

(5.6786%)

since

2025/06/30

4.

FMR Inc

(5.0492%)

since

2025/06/30

5.

State Street Corp

(4.4388%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.8181%)

since

2025/07/31

7.

Geode Capital Management, LLC

(2.2816%)

since

2025/06/30

8.

Scottish Mortgage Ord

(2.2183%)

since

2025/06/30

9.

Vanguard Small Cap Index

(2.172%)

since

2025/07/31

10.

Vanguard 500 Index Investor

(2.1659%)

since

2025/07/31

11.

Morgan Stanley - Brokerage Accounts

(2.0827%)

since

2025/06/30

12.

Theleme Partners LLP

(2.0224%)

since

2025/06/30

13.

Two Sigma Advisers, LLC

(2.0088%)

since

2025/06/30

14.

D. E. Shaw & Co LP

(1.9183%)

since

2025/06/30

15.

Amvescap Plc.

(1.8251%)

since

2025/06/30

16.

Two Sigma Investments LLC

(1.7886%)

since

2025/06/30

17.

Fidelity Growth Compy Commingled Pl S

(1.749%)

since

2025/07/31

18.

Vanguard International Growth Inv

(1.6451%)

since

2025/06/30

19.

Vanguard Small Cap Value Index Inv

(1.3973%)

since

2025/07/31

20.

Invesco S&P 500® Equal Weight ETF

(1.3104%)

since

2025/08/29

21.

Fidelity Growth Company Fund

(1.2952%)

since

2025/07/31

22.

Flagship Ventures Management, Inc.

(1.1905%)

since

2025/06/30

23.

Fidelity 500 Index

(1.1088%)

since

2025/07/31

24.

SPDR® S&P Biotech ETF

(1.0865%)

since

2025/08/31

25.

SPDR® S&P 500® ETF

(1.0538%)

since

2025/08/31

26.

iShares Core S&P 500 ETF

(1.0526%)

since

2025/08/31

27.

UBS Group AG

(1.0132%)

since

2025/06/30

28.

Jane Street Group LLC

(0.972%)

since

2025/06/30

29.

NORGES BANK

(0.8841%)

since

2025/06/30

30.

VOLORIDGE INVESTMENT MANAGEMENT, LLC

(0.8747%)

since

2025/06/30

31.

Goldman Sachs Group Inc

(0.8747%)

since

2025/06/30

32.

Banque Pictet & Cie SA

(0.8052%)

since

2025/06/30

33.

Northern Trust Corp

(0.7943%)

since

2025/06/30

34.

Baillie Gifford US Equity Growth

(0.7343%)

since

2024/12/31

35.

Vanguard US Growth Investor

(0.6924%)

since

2025/06/30

36.

The Health Care Select Sector SPDR® ETF

(0.5973%)

since

2025/08/31

37.

Vanguard Institutional Index I

(0.5297%)

since

2025/07/31

38.

iShares Biotechnology ETF

(0.525%)

since

2025/08/31

39.

State St S&P 500® Indx SL Cl III

(0.467%)

since

2025/08/31

40.

BB Biotech AG Ord

(0.4112%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.51

EPS Estimate

-2.05

EPS Difference

1.54

Surprise Percent

75.122%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.